Video

Dr. Richard Carvajal on Selumetinib/ Dacarbazine in Uveal Melanoma

Author(s):

Richard D. Carvajal, MD

In Partnership With:

Richard Carvajal, MD, Director of Experimental Therapeutics and Director of the Melanoma Service at Columbia University Medical Center, discusses the phase III SUMIT trial, a randomized, placebo-controlled, double-blind trial of selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma.

Richard Carvajal, MD, Director of Experimental Therapeutics and Director of the Melanoma Service at Columbia University Medical Center, discusses the phase III SUMIT trial, a randomized, placebo-controlled, double-blind trial of selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma.

Ocular, or uveal melanoma as it is also known, is very treatment refractory when compared to cutaneous melanoma. Currently there are no approved systemic treatment options for patients with metastatic disease.

The SUMIT trial built on pre-clinical data and clinical data showing that MEK-inhibitor would be an effective data. The primary endpoint was progression-free survival (PFS).

However, the study demonstrated no different in median PFS between the experimental and control arms.

Related Videos
Andrew Ip, MD
Mansi R. Shah, MD
Elizabeth Buchbinder, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Alec Watson, MD
Sagar D. Sardesai, MBBS
Ashkan Emadi, MD, PhD
Matthew J. Baker, PhD
Manmeet Ahluwalia, MD, MBA, FASCO
John Mascarenhas, MD
Related Content
Jennifer Amengual, MD, Herbert Irving Assistant Professor of Medicine, Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center
December 3rd 2024

Research Provides Insights Into Real-World CAR T-Cell Therapy and Bispecific Antibody Use in DLBCL

Alexey Danilov, MD, PhD, Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director, Early Phase Therapeutics Program, Systems Clinical Trials Office, co-director, Toni Stephenson Lymphoma Center, professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope; Nicole Lamanna, MD, associate clinical professor, medicine, Hematologic Malignancies Section, Hematology/Oncology Division, Columbia University Herberg Irving Comprehensive Cancer Center
November 25th 2024

Long-Term Data Solidify the Role of Zanubrutinib in R/R CLL: With Alexey Danilov, MD, PhD; and Nicole Lamanna, MD

Suzanne Lentzsch, MD, PhD
August 15th 2024

Linvoseltamab Demonstrates Deep, Durable Responses in R/R Myeloma Ahead of FDA Action Date

Ian Flinn, MD, PhD; Nicole Lamanna, MD; Jennifer R. Brown, MD, PhD; Constantine Tam, MD, MBBS
February 16th 2023

FDA Approval Insights: Zanubrutinib in CLL and SLL

Sunil Iyer, MD, of Columbia University Irving Medical Center
March 28th 2024

Imetelstat Shows Potential to Transform QOL in Lower-Risk MDS

Sunil Iyer, MD
March 26th 2024

Luspatercept Provides Effective First-Line Alternative to ESAs in Lower-Risk MDS